Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: sleep
- Who it enrolls
- age 18 Years to 60 Years; excludes diabetes; no BMI minimum stated; conditions: Sleep Apnea, Obstructive
- Interventions
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml; Continuous positive airway pressure treatment; Liraglutide and CPAP
- Conditions
- Sleep Apnea, Obstructive
- Phase and size
- NA · 30 participants
- Dates
- Start 2019-12-02
Primary completion 2021-12-31 - Sponsor
- St Vincent's University Hospital, Ireland (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Insulin resistance6 months
Published results in the collection
- Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept StudyRandomized trial · 2024 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
02Eligibility
Who can take part
Inclusion Criteria: * Newly diagnosed moderate-severe OSA (by standard PSG) * Body mass index between 30 - 40 * Age 18 - 60 years * Able to provide written, informed consent Exclusion Criteria: * Pregnancy * Requirement for supplemental oxygen * Previous diagnosis of OSA or previous CPAP treatment * Diagnosis of Diabetes * Previous treatment with GLP-1 analogue * Previous surgical treatment for obesity * Active treatment for malignancy or severe psychiatric disorder * Acute coronary syndrome or stroke within 3 months prior to study * History of decompensated heart failure * Professional drivers or drivers with a history of road-traffic accident due to sleepiness * Severe excessive daytime sleepiness defined as Epworth sleepiness scale \>15
03Change log
Registry changes
No changes recorded since the trial was added.